Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 proof-of-concept study of oral OLT1177 for acute gout flare
NL-OMON47412Phase 2Active, not recruiting
- Sponsor
- Olatec Therapeutics LLC
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dapansutrile in gout (4 cohorts), sponsored by Olatec Therapeutics LLC. Primary endpoint: Change in target joint pain intensity from baseline to Day 3 evening. Started May 2017; status: active, not recruiting.
02
Drugs
dapansutrile
03
Conditions
gout
Beyond the preview
Go deeper on NL-OMON47412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47412.